Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Inclusion Criteria

• •Postmenopausal according to standard clinical criteria OR receiving concomitant LHRH agonist therapy.
• •Taking aromatase inhibitor therapy (anastrozole, exemestane, or letrozole) for adjuvant treatment of breast cancer or for chemoprevention for at least 3 weeks and no more than 2 years at the time of enrollment.
• •Planning to take the same AI therapy for at least 15 weeks.
• •New or worsening joint pain and/or myalgias since starting the AI therapy.
• •Completion of surgery (mastectomy or lumpectomy/partial mastectomy) for treatment of breast cancer at least 3 months prior to enrollment.